Thyroid Cancer Clinical Trials in Boston, Massachusetts
10 recruitingBoston, Massachusetts
Showing 1–10 of 10 trials
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled82 locationsNCT05538130
Recruiting
Not Applicable
Hereditary Risk Factors for Thyroid Cancer
Thyroid Cancer
Dana-Farber Cancer Institute250 enrolled1 locationNCT02747888
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
MelanomaNon-small Cell Lung CancerThyroid Cancer+2 more
Pfizer267 enrolled40 locationsNCT05355701
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Breast CancerEsophageal CancerPancreatic Cancer+13 more
ModeX Therapeutics, An OPKO Health Company285 enrolled6 locationsNCT06239194
Recruiting
Not Applicable
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
MelanomaBreast Cancer, NOSCNS Primary Tumor, NOS+9 more
Eastern Cooperative Oncology Group400 enrolled347 locationsNCT05108298
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Colorectal, CancerColorectal CarcinomaNon-small Cell Lung Cancer+29 more
Institut de Recherches Internationales Servier554 enrolled11 locationsNCT05786924
Recruiting
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Pediatric CancerPapillary Thyroid CancerDifferentiated Thyroid Cancer
Children's Hospital of Philadelphia32 enrolled9 locationsNCT05024929
Recruiting
Phase 1
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Thyroid CancerBRAF Mutation-Related TumorsAnaplastic Thyroid Cancer
UNC Lineberger Comprehensive Cancer Center12 enrolled2 locationsNCT06902376
Recruiting
Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Pancreatic CancerGastric CancerLung Cancer+15 more
Apollomics Inc.497 enrolled35 locationsNCT03175224
Recruiting
Phase 2
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Thyroid CancerThyroid CarcinomaPapillary Thyroid Cancer+3 more
Massachusetts General Hospital30 enrolled6 locationsNCT05668962